Abstract:Abstractβ-Amyloid (Aβ) peptide fibrillation, one of the characteristic hallmarks of Alzheimer’s disease, is determined by many interfacial physical-chemical factors, e.g., charge, hydrophobicity, etc. Despite extensive research, chiral effect in different-scales on the fibrillation process of Aβ remains unclear. Herein, molecular-scale, sub-nanoscale, and nanoscale chiral-structures were constructed to investigate their chiral effect on the fibrillation of Aβ40 peptides. Chiral structures from molecular-scale to nanoscale were obtained from the different periods of the chemosynthesis process of chiral ZnS quantum-dots (QDs), confirmed by real-time monitoring of circular dichroism spectra. For molecular-scale, both L-penicillamine (L-P) and D-P ligands accelerated the fibrillation of Aβ40, and the speed-up effect of D-P was slightly stronger than L-P. For sub-nanoscale, both two chiral Zn-complexes (L-Zn and D-Zn) induced the agglomeration of Aβ40 without chirality discrimination. For nanoscale, both L-ZnS and D-ZnS QDs inhibited the fibrillation of Aβ40, and the inhibition effect of L-ZnS was notably better than that of D-ZnS. In-situ kinetics experiments of Aβ40 co-incubated with two chiral QDs demonstrated that L-ZnS completely prevents the misfolding of Aβ40 from unfolded to β-sheet, while D-ZnS cannot achieve this. Further site-replacement experiments and simulation results revealed the underlying molecular mechanisms of the different inhibition efficiency of chiral ZnS QDs on Aβ40 fibrillation, which mainly attribute to the stereoselectivity interaction between the chiral ligands of ZnS QDs and electro-positive amino acid residues (R5, K16, and K28) of Aβ40. This work offers a microscopic insight of chiral effect on Aβ fibrillation exerted by structures in different-scales, and provides a guidance in precise regulation of protein fibrillation via manipulating chiral structures in different-scales.

Discovering Effective Chiral Dipeptides against Aβ(1-42) Aggregation by the Computational Screening Strategy

Identification of Novel Oligopeptides from the Simulated Digestion of Sea Cucumber (stichopus Japonicus) to Alleviate Aβ Aggregation Progression

Inhibitor discovery targeting the intermediate structure of beta-amyloid peptide on the conformational transition pathway: implications in the aggregation mechanism of beta-amyloid peptide.

Inhibitor discovery targeting the intermediate structure of β-amyloid peptide on the conformational transition pathway: Implications in the aggregation mechanism of β-amyloid peptide

Molecular Integrative Analysis of the Inhibitory Effects of Dipeptides on Amyloid β Peptide 1–42 Polymerization

Discovery of New Selective Butyrylcholinesterase (BChE) Inhibitors with Anti-Aβ Aggregation Activity: Structure-Based Virtual Screening, Hit Optimization and Biological Evaluation

Structural Optimization and Biological Evaluation of Substituted Bisphenol A Derivatives As Beta-Amyloid Peptide Aggregation Inhibitors.

An enzyme-linked immunosorbent assay to compare the affinity of chemical compounds for β-amyloid peptide as a monomer

Searching for the Multi-Target-Directed Ligands Against Alzheimer’s Disease: Discovery of Quinoxaline-Based Hybrid Compounds with AChE, H3R and BACE 1 Inhibitory Activities

Porous organic cage as an inhibitor of Aβ42 peptide: a simulation study

Targeting the Amyloid-β Fibril Surface with a Constrained Helical Peptide Inhibitor.

Recent Studies On Mechanisms Of New Drug Candidates For Alzheimer'S Disease Interacting With Amyloid-Beta Protofibrils Using Molecular Dynamics Simulations

Aβ42-binding peptoids as amyloid aggregation inhibitors and detection ligands.

Chiral effect on Aβ fibrillation from molecular-scale to nanoscale

Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and beta-secretase

Toward the Mode of Action of the Clinical Stage All-d-Enantiomeric Peptide RD2 on Aβ42 Aggregation

Bifunctional backbone modified squaramide dipeptides as amyloid beta (Aβ) aggregation inhibitors

Mechanism Exploration of Amyloid-β-42 Disaggregation by Single-Chain Variable Fragments of Alzheimer's Disease Therapeutic Antibodies.

Α-Helical Motif As Inhibitors of Toxic Amyloid-β Oligomer Generation Via Highly Specific Recognition of Amyloid Surface

Mechanism Exploration of Amyloid-β-42 Disaggregation by Single-Chain Variable Fragments of Alzheimer’s Disease Therapeutic Antibodies

Discovery of new multifunctional selective acetylcholinesterase inhibitors: structure-based virtual screening and biological evaluation